# GSK regulatory submission for momelotinib accepted for review in Japan

- Link: https://www.directorstalkinterviews.com/gsk-regulatory-submission-for-momelotinib-accepted-for-review-in-japan/4121127023
- Published: 2023-09-11T07:28:34+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that the Ministry of Health, Labour and Welfare (MHLW),
Japan, has accepted for review a new drug application (NDA) for momelotinib, a potential
new medicine with a differentiated mechanism of action that may address the significant
medical needs of myelofibrosis patients, especially those with anaemia. The NDA 
is based on data from the pivotal phase III trials SIMPLIFY-1 and MOMENTUM.

·   Regulatory submission included data from pivotal trials addressing key clinical
manifestations of myelofibrosis, namely splenomegaly, constitutional symptoms and
anaemia

Myelofibrosis is a blood cancer that can lead to splenomegaly (enlarged spleen);
constitutional symptoms such as fatigue, night sweats, and bone pain; and severely
low blood counts, including anaemia and thrombocytopenia.^([1],[2],[3]) About 70%
of patients diagnosed with primary myelofibrosis and about half of patients diagnosed
with secondary myelofibrosis in Japan have moderate to severe anaemia at the time
of diagnosis, and nearly all patients are estimated to develop anaemia over the 
course of the disease.^([4],[5],[6],[7],[8],[9]) Patients who are transfusion dependent
have a poor prognosis and shortened survival.^([10],[11],[12],[13],[14],[15],[16],[
17],[18])

Momelotinib is not currently approved in any market.

**About momelotinib**

Momelotinib has a differentiated mechanism of action, with inhibitory ability along
three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor,
type I (ACVR1).^([19],[20],[21],[22]) Inhibition of JAK1 and JAK2 may improve constitutional
symptoms and splenomegaly.^(19,21,22) Additionally, inhibition of ACVR1 leads to
a decrease in circulating hepcidin, which is elevated in myelofibrosis and contributes
to anaemia.^(19,20,21,22)

**About myelofibrosis**

Myelofibrosis is a rare blood cancer that disrupts the body’s normal production 
of blood cells as a result of dysregulated JAK-signal transducer and activator of
transcription protein signalling. The clinical hallmarks of myelofibrosis are progressive
splenomegaly (enlarged spleen), anaemia and debilitating symptoms attributable to
ineffective hematopoiesis and excessive production of proinflammatory cytokines.
^([23]) Myelofibrosis patients with anaemia require additional supportive care, 
including transfusions, and have poor outcomes.^([24],[25]) Myelofibrosis affects
approximately 1 in 500,000 people worldwide, with up to 5,000 patients impacted 
in Japan.^(10,19,[26],[27])

**About the pivotal SIMPLIFY-1 clinical trial**

SIMPLIFY-1 was a multicentre randomised, double-blind, phase III study that compared
the safety and efficacy of momelotinib to ruxolitinib in patients with myelofibrosis
who had not received prior treatment with a JAK inhibitor. SIMPLIFY-1 met its primary
endpoint, demonstrating non-inferiority of momelotinib to ruxolitinib in spleen 
volume response (reduction by 35% or greater), and substantial improvements in transfusion
independence rates.^([28],[29])

**About the pivotal MOMENTUM clinical trial**

MOMENTUM was a global, randomised, double-blind phase III clinical trial of momelotinib(
MMB) versus danazol (DAN) in patients with myelofibrosis who were symptomatic and
anaemic and had been previously treated with an approved JAK inhibitor. The MOMENTUM
trial met all its primary and key secondary endpoints, with respect to splenic response,
constitutional symptoms and transfusion independence. Results from the 24-week treatment
period were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual
Meeting and subsequently published in _The Lancet_ (https://www.thelancet.com/journals/
lancet/article/PIIS0140-6736(22)02036-0/fulltext).^(22,[30])

[1] NIH National Library of Medicine. Primary Myelofibrosis. September 2014. Accessed
5 August 2022. https://medlineplus.gov/genetics/condition/primary-myelofibrosis/

[2] MPN Research Foundation. Primary Myelofibrosis (PMF). 2021. Accessed August,
2022. http://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/

[3] National Organization for Rare Disorders (NORD). Primary Myelofibrosis. 2018.
Accessed 9 August 2022. https://rarediseases.org/rare-diseases/primary-myelofibrosis/

[4] Takenaka K et al., Clinical features and outcomes of patients with primary myelofibrosis
in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic
Organs Research Committee of Japan. Int J Hematol. 2017 Jan;105(1):59-69. doi: 10.1007/
s12185-016-2102-3

[5] Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis:
the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25-33. doi:10.1016/j.mayocp.
2011.11.001

[6] Bose P, et al. Curr Hematol Malign Rep. 2018;13:164-172. doi: https://doi.org/
10.3109/10428194.2013.813500

[7] Scherber, R.M., Mesa, R. Management of challenging myelofibrosis after JAK inhibitor
failure and/or progression. Blood Rev. 2020;42:100716. https://doi.org/10.1016/j.
blre.2020.100716

[8] Bassiony S, Harrison CN, McLornan DP. Evaluating the Safety, Efficacy, and Therapeutic
Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis:
Evidence to Date. Ther Clin Risk Manag. 2020;16:889-901. Published 2020 Sep 25. 
doi:10.2147/TCRM.S258704

[9] Shide K et al. Nationwide prospective survey of secondary myelofibrosis in Japan:
superiority of DIPSS-plus to MYSEC-PM as a survival risk model. Blood Cancer J. 
2023;13(1):110. doi: 10.1038/s41408-023-00869-9

[10] Naymagon, L., Mascarenhas, J. Myelofibrosis-Related Anemia: Current and Emerging
Therapeutic Strategies. HemaSphere. 2017;1(1):e1. doi: 10.1097/HS9.0000000000000001

[11] How J, Hobbs GS. A Practical Guide for Using Myelofibrosis Prognostic Models
in the Clinic. J Natl Compr Canc Netw. 2020;18(9):1271-1278. https://doi.org/10.6004/
jnccn.2020.7557

[12] Nicolosi M, et al. Sex and degree of severity influence the prognostic impact
of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients.
Leukemia. 2018;32(5):1254-1258. https://doi.org/10.1038/s41375-018-0028-x

[13] Tefferi A, et al. Use of the Functional Assessment of Cancer Therapy–anemia
in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Clin Ther. 2014;36(4):560-566. https://doi.org/10.1016/j.clinthera.2014.02.016

[14] Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification
and management. Am J Hematol. 2021;96(1):145-162. https://doi.org/10.1002/ajh.26050

[15] Rumi E, et al. The Genetic Basis of Primary Myelofibrosis and Its Clinical 
Relevance. Int J Mol Sci. 2020;21(23):8885. https://doi.org/10.3390/ijms21238885

[16] QxMD. DIPSS prognosis in myelofibrosis. Accessed September 12, 2022. https://
qxmd.com/calculate/calculator_187/dipss-prognosis-in-myelofibrosis.

[17] QxMD. DIPSS plus score for prognosis of myelofibrosis. Accessed September 12,
2022.

[18] Elena C, et al. Red blood cell transfusion-dependency implies a poor survival
in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96(
1):167-170. https://doi.org/10.3324/haematol.2010.031831

[19] Chifotides, HT, Bose, P, Verstovsek, S. Momelotinib: an emerging treatment 
for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(7):1-18.

[20] Asshoff M, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production,
and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823-1830.

[21] Oh S, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency
and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282-
4291.

[22] Verstovsek S, et al. Momelotinib versus danazol in symptomatic patients with
anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind,
randomised, controlled, phase 3 study. The Lancet. 2023;401(10373):269-280.

[23] Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg
Drugs. 2012 Dec;17(4):555-70. doi: 10.1517/14728214.2012.748748. PMID: 23186315;
PMCID: PMC5009610.

[24] Chifotides, H.T., Bose, P. & Verstovsek, S. Momelotinib: an emerging treatment
for myelofibrosis patients with anemia. J Hematol Oncol 15, 7 (2022). https://doi.
org/10.1186/s13045-021-01157-4

[25] Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current and Emerging
Therapeutic Strategies. Hemasphere. 2017 Dec 20;1(1):e1. doi: 10.1097/HS9.0000000000000001.
PMID: 31723730; PMCID: PMC6745971.

[26] Data on file. Sierra Oncology. 2021.

[27] Myelofibrosis – Epidemiology Forecast – 2032. DelveInsight. 2022;1-60.

[28] Mesa R, et al. Presented at: ISPOR 2021.

[29] Mesa R, et al. Presented at: SOHO 2021. Poster MPN-303.

[30] Mesa R, et al. Presented at: American Society of Clinical Oncology; June 2022.
Abstract 7002.

Share on: